Fresh analysis reveals that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who stop traditional lifestyle regimens.
Research printed in a major health publication points out that while overweight individuals frequently drop a large proportion of their total mass while on the medication, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Users using these treatments should be informed of the risk of fast rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a return to pre-treatment weight in about one and a half years.
Analyzing Therapies
The analysis, which looked at 37 of trials involving thousands of patients, contrasted the results of the injectable medications with conventional dieting.
Researchers emphasize that individuals who lose weight through diet and exercise typically have a less rapid creep back—around 100 grams monthly—after stopping.
The Reason for the Rapid Regain
Experts suggest the mode of action of the jabs explains the heightened regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of the hormone concentrations several times higher than normal might result in the body to produce less of its endogenous GLP-1, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication results in hunger is unsuppressed, making excessive eating a significant risk."
A Chronic Condition?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
Many experts contend that, considering the high risk of weight regain, the treatment might need to be ongoing.
This view is echoed by pharmaceutical companies, who note that the results "highlight the chronic nature of obesity," similar to managing conditions like hypertension.
User Accounts
Individuals who have discontinued the medication report a intense resurgence of hunger.
"I experienced a switch flipping and you become extremely hungry," described an individual.
The struggle is compounded if patients have not adopted lasting dietary or behavioural changes during treatment.
Growing Adoption
Figures show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is more common among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
In conclusion, clinicians stress that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone solution and maintained weight loss hinges on integrated behavioural support.
